IL17A and inflammatory bowel disease: Increasing cases of induction or exacerbation of IBD have been reported among patients treated with drugs inhibiting IL-17 (Caron et al., 2022; Burisch et al., 2020), which suggests that rheumatologists and dermatologists should increase awareness of the risk and improve safety measures to prevent drug-induced IBD, as well as evaluate patients carefully to identify any contraindications before the initiation of IL-17 inhibitor therapy for psoriasis and/or rheumatological diseases (Felice et al., 2019).